

LIST OF TABLES

Table No.	Table Captions	Page No.
CHAPTER-I		
1.1	Some drugs developed from natural products	3
1.2	Lead compounds isolated from medicinal plants	7
1.3	Some examples of commercial anticoagulant drugs	12
1.4	Some examples of commercial thrombolytic drugs	14
1.5	Some examples of commercial antiplatelet drugs	15
1.6	Some pharmacological activities of the selected medicinal plants	17
CHAPTER-II		
2.1	Inhibition on the coagulation pathways by some plant-derived natural products.	44
2.2	Inhibition of platelet membrane receptors by natural products from plants.	47
CHAPTER-III		
3.1	Code used of the different plant extracts.	70
3.2	Composition of Tris-glycine SDS-PAGE.	74
3.3	Composition of running buffer.	74
3.4	Composition of 3X loading dye.	74
CHAPTER-IV		
4.1	Anticoagulant activity shown by different extracts.	105
4.2	Anticoagulant activity of aqueous extract <i>L. indica</i> and <i>M. charantia</i> under different extraction conditions.	106
4.3	Summary of purification of AFLI from aqueous leaves extract of <i>L. indica</i> .	109
4.4	Analysis of AFLI by GC-MS to identify its major constituents.	110
4.5	Anticoagulant and antithrombin (in terms of fibrinogen clotting time of thrombin) activities of the AFLI and AAP.	112
4.6	A comparison of the <i>in vitro</i> thrombolytic activity among AAP, nattokinase, plasmin, and streptokinase under identical experimental conditions.	122
4.7	A comparison of behavioral and physical parameters in AAP-treated mice. The AAP at a dose of 2000 mg/kg was orally administered to mice for 7 days	125
4.8	Hematological parameters of AAP-treated (2000 mg/kg) and control group of mice after 7 days of oral administration of AAP	126
4.9	Some biochemical properties of serum of control and AAP-treated (2000 mg/kg) mice after 7 days of oral administration of AAP.	127
4.10	Serum immunoglobulin parameters of the AAP-treated (2000 mg/kg) mice after 7 days of oral administration.	127

Table No.	Table Captions	Page No.
4.11	A comparison of <i>in vivo</i> anticoagulant activity of AAP and nattokinase treated Swiss albino mice (n=6).	130
4.12	The effect of AAP and nattokinase on k-carrageenan induced mice tail thrombus model at 24, 48 and 72 h post treatment.	131
CHAPTER-V		
5.1	A summary of purification of lunathrombase from aqueous leaves extract of <i>L. indica</i> .	145
5.2	Amino acids composition of lunathrombase (% nmol). Values are mean of triplicate determinations	147
5.3	Effect of FPA and FPB on fibrinogenolytic activity of lunathrombase. Values are mean \pm SD of triplicate determinations.	153
5.4	The substrate specificity of lunathrombase at 37 °C, pH 7.4.	153
5.5	Effect of inhibitors on fibrinogenolytic activity of lunathrombase.	156
5.6	Behavioral and physical changes in lunathrombase treated rats (10 mg/kg) after <i>i.p</i> injection	173
5.7	Serum hematological parameters of lunathrombase-treated (10 mg/kg) and control group of rats after 72 hours of <i>i.p.</i> injection.	174
5.8	Some biochemical properties of serum of control and lunathrombase-treated (10 mg/kg) rats after 72 hours of <i>i.p.</i> injection.	175
5.9	Serum immunoglobulin parameters of the lunathrombase-treated (10.0 mg/kg) rats after 72 hours of <i>i.p.</i> injection.	175
5.10	A comparison of <i>in vivo</i> anticoagulant activity of lunathrombase, heparin and Nattokinase treated Wister strain rats (n=6).	178
CHAPTER-VI		
6.1	Comparison of <i>in vitro</i> thrombolytic activity shown by BSS, plasmin, streptokinase, and nattokinase under identical experimental conditions.	204
6.2	Comparison of <i>in vivo</i> anticoagulant activity of BSS, heparin, nattokinase, and argatroban-treated Swiss albino mice.	207
6.3	The effect of BSS and nattokinase on k-carrageenan-induced mouse tail thrombus model at 24, 48, and 72 h post treatment.	209
CHAPTER-VII		
7.1	Effect of chemical inhibitors on fibrin(ogen)olytic activity of AAF.	225
7.2	A comparison of the <i>in vitro</i> thrombolytic activity shown by AAF, nattokinase, and streptokinase under identical experimental conditions.	229
7.3	Phytochemical analysis of AAF.	231
7.4	Amino acids composition of AAF (% nmol).	232
7.5	The proteins identified in the lower and upper SDS-PAGE protein bands of the AAF after LC-MS/MS analysis	233

Table No.	Table Captions	Page No.
7.6	Peptide sequences detected for the proteins identified by LC-MS/MS analysis	233
7.7	GC-MS analysis of AAF	235
7.8	A comparison of <i>in vivo</i> anticoagulant and defibrinogenating activity of AAF and nattokinase-treated Swiss Albino mice.	238
7.9	The effect of AAF and nattokinase on k-carrageenan induced mice tail thrombus model at 24, 48 and 72 h post treatment.	238

LIST OF FIGURES		
Figure No.	Figure Captions	Page No.
CHAPTER-I		
1.1	Overview on bioactivity-guided isolation.	4
1.2	Photographs of the selected plants	18
CHAPTER-II		
2.1	Blood coagulation pathway	41
CHAPTER-IV		
4.1a	Fractionation of crude aqueous shade leaves extract of <i>L. indica</i> cation exchange on Prep TM anion exchange DEAE-cellulose FF 16/10 column.	107
4.1b	Fractionation of the anion-exchange unbound fraction (AEX_1 peak) on cation exchange CM-cellulose (20 mm X 60 mm) column	108
4.1c	Gel filtration chromatography of the AFLI on Shodex KW-803 column (5 µm, 8 x 300 mm)	108
4.2	12.5% SDS-PAGE analysis of AFLI.	111
4.3a	Dose- dependent <i>in vitro</i> anticoagulant activity of AAP/AFLI against human PPP	113
4.3b	Time- dependent anticoagulant activity by AAP against human PPP	114
4.3c	Comparison of <i>in vitro</i> anticoagulant activity of AAP, warfarin, heparin, nattokinase, and argatroban against goat PPP	114
4.3d	The <i>in vitro</i> effect of AAP on APTT and PT time of PPP from human blood	115
4.4a	Effect of AAP (1.0 µg/ml) on amidolytic activity of thrombin (36.6 nM) against its chromogenic substrate T1637 (0.2 mM)	116
4.4b	Effect of AAP (1.0 µg/ml) on amidolytic activity of FXa (0.13 mM) against its chromogenic substrate F3301 (0.2 mM)	116
4.4c	Dose-dependent (0.25-5 µg/ml) inhibition of fibrinogen clotting time of thrombin by AAP at 37 °C, pH 7.4	117
4.4d	Time-dependent inhibition of fibrinogen clotting time of thrombin by AAP (1.0 µg/ml) at 37 °C, pH 7.4.	117
4.4e	Inhibition of prothrombin activation property of FXa by AAP	118
4.5a	Kinetics of fibrinogenolytic activity of AAP	119
4.5b	Kinetics of fibrinolytic activity of AAP	119
4.6a	Fluorescence spectra showing interaction of thrombin (1.0 µg/ml) with different concentrations of AAP	120
4.6b	Fluorescence spectra showing interaction of FXa (1.0 µg/ml) with different concentrations of AAP (1.0-5.0 µg/ml)	120
4.6c	Fluorescence spectra showing interaction of fibrinogen (1.0 µg/ml) with different concentrations of AAP (1.0-5.0 µg/ml)	121
4.7a	<i>In vitro</i> hemolysis assay of AAP	123
4.7b	<i>In vitro</i> cell viability by MTT assay	123
4.7c	Effect of AAP (100 µg/ml) on different Cytochrome P450 isoforms	124

Figure No.	Figure Captions	Page No.
4.8	Dose-dependent platelet deaggregation by AAP/aspirin	124
4.9	Dose-dependent inhibition of collagen/ADP-induced platelet aggregation by AAP	125
4.10	Light microscopic observation of the effect of AAP on liver, kidney, and heart tissues of mice	129
4.11	Dose-dependent <i>in vivo</i> defibrinogenating activity of AAP after 5 h of oral administration in mice (n=6)	129

CHAPTER-V

5.1a	Fractionation of crude aqueous shade leave extract of <i>L. indica</i> on a PrepTM anion exchange DEAE-cellulose FF 16/10 column	142
5.1b	Fractionation of the anion-exchange unbound fraction (AEX_1 peak) on cation exchange CM-cellulose (20 mm X 60 mm) column	143
5.1c	Gel filtration of the CEX_1 on Shodex KW-803 column (5 μ m, 8 x 300 mm).	143
5.1d	Determination of purity and molecular mass of AF_GF3 (lunathrombase) by 12.5% SDS-PAGE	144
5.1e	MALDI-ToF mass spectra of lunathrombase	144
5.1f	Multiple sequence alignment of tryptic fragment of lunathrombase with homologous proteins deposited in the NCBI database	146
5.1g	Circular dichroism (CD) spectra of lunathrombase	147
5.2a	Dose- dependent <i>in vitro</i> anticoagulant activity of lunathrombase against human platelet-poor plasma	148
5.2b	Time- dependent anticoagulant activity by lunathrombase (400 nM) against human PPP	148
5.2c	Effect of lunathrombase (50-600 nM) on APTT and PT of PPP isolated from human blood	149
5.3a	Kinetics of fibrinolytic activity of lunathrombase	150
5.3b	A comparison of fibrinolytic activity among lunathrombase, nattokinase, plasmin, and thrombin under identical conditions by 12.5% SDS-PAGE analysis	150
5.3c	Determination of fibrinolytic activity of lunathrombase, nattokinase, streptokinase, and plasmin under identical experimental conditions by 12.5% SDS-PAGE analysis	151
5.3d	Determination of <i>K_m</i> and <i>V_{max}</i> values of lunathrombase against fibrinogen	151
5.3e	Determination of <i>K_m</i> and <i>V_{max}</i> values of nattokinase against fibrinogen	152
5.3f	A comparison of fibrinogen degradation under identical experimental conditions between nattokinase and lunathrombase by RP-UHPLC analysis	152
5.4a	Effect of temperature (10-80 °C) on fibrin(ogen)olytic activity of lunathrombase	154
5.4b	Influence of pH (2-12) on fibrin(ogen)olytic activity of lunathrombase	154

Figure No.	Figure Captions	Page No.
5.4c	Degradation of fibronectin, laminin, and type-IV collagen by lunathrombase	154
5.5	Determination of glycosylation in lunathrombase	155
5.6a	Effect of metal ions (2 mM) on fibrin(ogen)olytic activity of lunathrombase	156
5.6b	The effect of inhibitors on fibrinogenolytic activity of lunathrombase	157
5.7a	Effect of lunathrombase (0.2 μ M) on amidolytic activity of thrombin (36.6 nM) against its chromogenic substrate T1637 (0.2 mM)	158
5.7b	Lineweaver-Burk and Michaelis-Menton (inset) plot showing inhibition of amidolytic activity of thrombin towards T1637 (0.2mM) by lunathrombase (0- 0.4 μ M)	158
5.7c	Effect of lunathrombase (0.2 μ M) on amidolytic activity of FXa (0.13 μ M) against its chromogenic substrate F3301 (0.2 mM)	159
5.7d	Lineweaver-Burk and Michaelis-Menton (inset) plot showing inhibition of amidolytic activity of FXa towards F3301 (0.2 mM) by lunathrombase (0- 0.4 μ M).	159
5.7e	Dose-dependent (25-600 nM) inhibition of fibrinogen clotting activity of thrombin by lunathrombase at 37 °C, pH 7.4	160
5.7f	Time- dependent inhibition of fibrinogen clotting time of thrombin by lunathrombase (100 nM) at 37 °C, pH 7.4	160
5.7g	Inhibition of prothrombin activation property of FXa by lunathrombase	161
5.8a	Fluorescence spectra showing interaction of thrombin (0.2 μ M) with different concentrations of lunathrombase (0.2-1.4 μ M).	162
5.8b	Fluorescence spectra showing interaction of FXa (0.2 μ M) with different concentrations of lunathrombase (0.2-1.4 μ M).	162
5.8c	Fluorescence spectra showing interaction of fibrinogen (0.2 μ M) with different concentrations of lunathrombase (0.2-1.4 μ M).	163
5.9a	ITC profile for lunathrombase (10 μ M) binding to thrombin (200 μ M).	164
5.9b	ITC profile for lunathrombase (10 μ M) binding to fibrinogen (200 μ M)	164
5.10	A comparison of <i>in vitro</i> thrombolytic activity of lunathrombase (1 μ M), streptokinase (1 μ M), plasmin (1 μ M), nattokinase (1 μ M) and tissue plasminogen activator (tPA) (1 μ M) under identical experimental conditions on heated and non-heated blood clots	165
5.11a	<i>In vitro</i> blood hemolysis assay	166
5.11b	<i>In vitro</i> cell viability by MTT assay	166
5.11c	Calcein-AM staining of HEK 293 cells	167
5.11d	Cell cycle analysis using propidium iodide (PI) staining and flow cytometry. HEK 293 cells	167
5.12a	Dose-dependent platelet deaggregation by lunathrombase / aspirin	168
5.12b	Dose-dependent inhibition of collagen / ADP / arachidonic acid - induced platelet aggregation by lunathrombase	168
5.12c	Percent aggregation / deaggregation of chymotrypsin-treated or untreated washed platelets (1 x 10 ⁶ cells).	169
5.12d	Binding of PMSF-inactivated lunathrombase (0.2 -1.0 μ M) to human fibrinogen (1000 ng), and human platelet GPIIb/IIIa receptor	170
5.13a-b	Effect of lunathrombase on thromboxane B ₂ and cAMP formation in activated platelets.	171
5.13c	Effect of lunathrombase on COX-1 activity	172

Figure No.	Figure Captions	Page No.
5.13d	Determination of <i>K_m</i> and <i>V_{max}</i> values of lunathrombase against COX-1 enzyme	172
5.14	Light microscopic observation of the effect of lunathrombase on liver, kidney, and heart tissues of Wistar rats	176
5.15	Dose- dependent <i>in vivo</i> defibrinogenating activity of lunathrombase	177

CHAPTER-VI

6.1	Chemical structure of β - sitosterol.	191
6.2a	Dose-dependent <i>in vitro</i> anticoagulant activity of BSS, warfarin, nattokinase, and argatroban against human platelet-poor plasma (PPP)	192
6.2b	Time-dependent <i>in vitro</i> anticoagulant activity of BSS (2.5 μ M) against human PPP	192
6.2c	Effect of BSS/argatroban (1.25-15.0 μ M) on PT of human PPP	193
6.2d	Effect of BSS/argatroban (1.25-15.0 μ M) on APTT of human PPP	193
6.2e	Dose-dependent <i>in vitro</i> whole blood clotting time of BSS and nattokinase against mammalian (goat) blood	194
6.3a	Effect of BSS (7.5 μ M) on amidolytic activity of thrombin (36.6 nM) against its chromogenic substrate T1637 (0.2 mM)	195
6.3b	Inhibition of fibrinogen clotting activity of thrombin (36.6 nM) by BSS (1.25-15 μ M) at 37°C, pH 7.4	195
6.3c	Time-dependent inhibition of fibrinogen clotting time of thrombin (36.6 nM) by BSS (7.5 μ M) at 37°C, pH 7.4	196
6.3d	Inhibition of amidolytic activity of thrombin against its substrate T1637	196
6.4a	Effect of BSS (7.5 μ M) on amidolytic activity of FXa (0.13 μ M) against its chromogenic substrate F3301 (0.2 mM).	197
6.4b	Inhibition of prothrombin activation property of FXa by BSS	197
6.5a	Dose-dependent platelet deaggregation by BSS/aspirin	198
6.5b	Effect of BSS on thrombin-induced platelet aggregation	199
6.6a	Interaction site of the BSS around the thrombin residues as determined by <i>in silico</i> study	200
6.7a,b	Fluorescence spectra showing interaction of thrombin and FXa with different concentrations of BSS	201
6.7c	Fluorescence spectra showing interaction of fibrinogen(0.2 μ M) with different concentrations of BSS	202
6.8	ITC profile for BSS (10 μ M) binding to thrombin (200 μ M)	203
6.9a	Effect of BSS (1.0 μ M) on the chromogenic substrate of plasmin	205
6.9b	Effect of BSS (1.0 μ M) on amidolytic activity of plasminogen (36.6 nM) against the chromogenic substrate of plasmin, V0882	205
6.10a	<i>In vitro</i> cell viability assay using MTT assay	206
6.10b	<i>In vitro</i> blood haemolysis assay	206
6.11	Dose- dependent <i>in vivo</i> defibrinogenating activity of BSS 5 h after <i>i.p.</i> injection in mice	208
6.12	The effect of BSS and nattokinase on κ -carrageenan-induced mouse tail thrombus length (48 h after κ -carrageenan injection).	208

Figure No.	Figure Captions	Page No.
CHAPTER-VII		
7.1a	Comparison of anticoagulant and fibrin(ogen)olytic activity	218
7.1b	Dose- dependent <i>in vitro</i> anticoagulant activity of AAF and whole fruit extracts of <i>M. charantia</i> against goat platelet-poor plasma	218
7.1c	Time- dependent <i>in vitro</i> anticoagulant activity of AAF (1.0 µg/ml) against goat PPP	219
7.1d	Comparison of <i>in vitro</i> anticoagulant activity of AAF, warfarin, heparin, and nattokinase against goat PPP	219
7.1e	Effect of AAF (0.5 - 1.0 µg/ml) on APTT and PT of goat PPP. Values are mean ± S.D. of triplicate determinations	220
7.2a	Kinetics of fibrinogenolytic activity of AAF and nattokinase. The degradation products were separated by 12.5% SDS-PAG	220
7.2b	Densitometry analysis to determine the percent degradation of fibrinogen	221
7.2c	Kinetics of fibrinolytic activity of AAF and Nattokinase	221
7.2d	Densitometry analysis to determine the percent degradation of fibrin	221
7.3a	Effect of substrate (fibrinogen) concentration on protease activity of AAF	222
7.3b	Comparison of time-dependent fibrinogen degradation between nattokinase and AAF by RP-UHPLC analysis	222
7.4a	Effect of AAF (1.0 µg/ml) on amidolytic activity of thrombin (36.6 nM) against its chromogenic substrate T1637 (0.2 mM).	223
7.4b	Effect of AAF (1.0-5.0 µg/ml) on fibrinogen clotting time of thrombin	223
7.4c	Effect of AAF (1.0 µg/ml) on amidolytic activity of FXa (1.0 µg/ml) against its chromogenic substrate F3301 (0.2 mM).	224
7.5a	Fluorescence spectra showing interaction of fibrinogen (1.0 µg/ml) with different concentrations of AAF (1.0-5.0 µg/ml).	226
7.5b	Fluorescence spectra showing interaction of fibrinogen (1.0 µg/ml) with different concentrations of rice husk (1.0-5.0 µg/ml)	226
7.5c	Fluorescence spectra showing interaction of thrombin (1.0 µg/ml) with different concentrations of AAF (1.0-5.0 µg/ml).	227
7.5d	Fluorescence spectra showing interaction of FXa (1.0 µg/ml) with different concentrations of AAF (1.0-5.0 µg/ml).	227
7.6a, b	Dose-dependent platelet deaggregation by AAF/aspirin	228
7.7a	Dose-dependent (1.25-15 µg/ml) <i>in vitro</i> whole blood clotting time of AAF, and nattokinase against mammalian (goat) blood	229
7.7b	<i>In vitro</i> cell viability assay by MTT assay	230
7.7c	<i>In vitro</i> hemolysis assay	230
7.8	12.5% SDS-PAGE analysis of AAF	232
7.9a-b	Anticoagulant and fibrinogenolytic activity of AAF (lyophilized) at different time intervals and in different storage conditions	236
7.10	Dose-dependent <i>in vivo</i> defibrinogenating activity of AAF 5 h after <i>i.v.</i> injection in mice	237
7.11	The effect of AAF and nattokinase on carrageenan-induced mice tail thrombus length (48 h after carrageenan injection).	237

ABBREVIATIONS

Abbreviation	Full form
1D SDS-PAGE	One dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis
2D SDS-PAGE	Two dimensional sodium dodecyl sulphate polyacrylamide gel electrophoresis
ACN	Acetonitrile
ADP	Adenosine diphosphate
AEX	Anion-exchange
ALC	Average local confidence
AMP	Adenosine monophosphate
APTT	Activated partial thromboplastin time
ARF	Acute renal failure
ATP	Adenosine triphosphate
BAEE	N α -benzoyl-L-arginine ethyl ester hydrochloride
BCIP/NBT	5-bromo-4-chloro-3'-indolyphosphate/nitro-blue tetrazolium
Bio-E	Biological E Limited
BLAST	Basic local alignment search tool
BNPP	bis- <i>p</i> -nitro-phenyl phosphate
BSA	Bovine serum albumin
BSS	B-sitosterol
CE-MS	Capillary electrophoresis-mass spectrometry
CID	Collision-induced dissociation
CO	Cyclooxygenase
CTAB	Cetrimonium bromide
CV	Column volumes
CVD	Cardiovascular disease
DFT	Density functional theory
DIC	Disseminated intravascular coagulopathy
DTT	Dithiothreitol
DVT	Deep vein thrombosis
EDTA	Ethylenediaminetetraacetic acid
ELISA	Enzyme-linked immunosorbent assay
ESI	Electrospray ionization
FPLC	Fast Protein Liquid Chromatography
FT	Fourier transform
FXa	Factor Xa
GBD	Global burden of disease
GC-MS	Gas chromatography - mass spectroscopy
GFC	Gel filtration chromatography
HEPES	4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HIT	Heparin-induced thrombocytopenia
IAA	Iodoacetamide

Abbreviation	Full form
IgA	Immunoglobulin A
IgG	Immunoglobulin G
IgM	Immunoglobulin M
ITC	Isothermal calorimetry
kDa	Kilodalton
kV	Kilo volt
LAAO	L-amino acid oxidase
LC-MS/MS	Liquid chromatography-tandem mass spectrometry
LD50	Median lethal dose
LMWH	Low molecular weight heparin
m/z	Mass to charge
MALDI-TOF-MS	Matrix-assisted laser desorption/ionization -Time of flight - mass spectrometry
MI	Myocardial infarction
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
MW	Molecular weight
NCBI	National Center for Biotechnology Information
NIH	National Institutes of Health
NSTEMI	Non-ST-segment elevation myocardial infarction
PBS	Phosphate buffered saline
PDE	Phosphodiesterase
Pi	Inorganic phosphate
PMSF	Phenylmethylsulfonyl fluoride
ppm	Parts per million
PE	Pulmonary embolism
PPP	Platelet poor plasma
PRP	Platelet rich plasma
PT	Prothrombin time
PTCA	Percutaneous transluminal coronaryangioplasty
PTM	Post translational modification
RP-HPLC	Reversed-phase high-performance liquid chromatography
RP-UHPLC	Reversed-phase ultra high-performance liquid chromatography
TAME	N α -p-tosyl-L-arginine methyl ester hydrochloride
TBS	Tris buffered saline
TCA	Trichloroacetic acid
TEMED	Tetramethylethylenediamine
TFA	Trifluoroacetic acid
TMB/H ₂ O ₂	3,3,5,5'-tetramethylbenzidine/hydrogen peroxide
TLCK	Tosyl-L-lysyl-chloromethane hydrochloride
TPCK	Tosyl phenylalanyl chloromethyl ketone
UA	Unstable angina
UFH	Unfractionated heparin
VTE	Venous thromboembolism

